Literature DB >> 20829622

Mortality in Cushing's disease.

R N Clayton1.   

Abstract

The causes of premature death in untreated Cushing's syndrome are vascular disease (myocardial infarction/stroke), uncontrolled diabetes mellitus and complications and infections. Long-term mortality outcome studies on pituitary-dependent Cushing's disease (CD) are limited to six studies in the English language literature. This paper reviews these studies on CD, other causes of Cushing's syndrome being excluded, because CD represents 80% of patients with the syndrome. The period covered by these studies (1970-1990) is when transsphenoidal surgery was well established as primary treatment for CD. Two studies were exclusively from surgical centres and are likely biased in favour of surgically resectable adenomas, so this needs to be borne in mind when interpreting their results. The criteria for remission of hypercortisolism and persistent disease were variable. The overall number of patients in each report is small, and the number of deaths even smaller by epidemiological standards giving very wide confidence intervals to the standardised mortality ratios (SMR). Moreover, follow-up time was relatively short (median 10-12 years) for a disease diagnosed in the patients' late 30s. Notwithstanding the above limitations of retrospective studies, and potential for positive bias, the overall SMR of around 1.5 was not significantly different from the relevant normal population for those patients deemed in remission. However, SMR was significantly worse for those patients with persistent disease. Where it was possible to analyse contributing factors to mortality, the presence of hypertension and diabetes mellitus, in addition to persistence of hypercortisolism, was shown to be significant. It remains possible that an overall SMR in 'cured' patients would be significant given a larger cohort, followed for longer, and with more deaths. What is clearly required is a multicentre prospective cohort study with >30 years' follow-up to answer the question definitively and identify the contributing factors in detail in order to achieve optimum long-term outcome.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20829622     DOI: 10.1159/000315813

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  11 in total

Review 1.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for refractory Cushing's disease.

Authors:  Alexander D Sherry; Mohamed H Khattab; Mark C Xu; Patrick Kelly; Joshua L Anderson; Guozhen Luo; Andrea L Utz; Lola B Chambless; Anthony J Cmelak; Albert Attia
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

4.  White blood cell count: a valuable tool for suspecting Cushing's syndrome.

Authors:  M Paja; I Merlo; J Rodríguez-Soto; E Cruz-Iglesias; M D Moure; C Elías; A Oleaga; N Egaña
Journal:  J Endocrinol Invest       Date:  2022-08-09       Impact factor: 5.467

5.  Death in pediatric Cushing syndrome is uncommon but still occurs.

Authors:  Alexandra Gkourogianni; Maya B Lodish; Mihail Zilbermint; Charalampos Lyssikatos; Elena Belyavskaya; Margaret F Keil; Constantine A Stratakis
Journal:  Eur J Pediatr       Date:  2014-09-23       Impact factor: 3.183

Review 6.  Neuropsychiatric disorders in Cushing's syndrome.

Authors:  Rosario Pivonello; Chiara Simeoli; Maria Cristina De Martino; Alessia Cozzolino; Monica De Leo; Davide Iacuaniello; Claudia Pivonello; Mariarosaria Negri; Maria Teresa Pellecchia; Felice Iasevoli; Annamaria Colao
Journal:  Front Neurosci       Date:  2015-04-20       Impact factor: 4.677

7.  Trabecular Bone Score Reflects Trabecular Microarchitecture Deterioration and Fragility Fracture in Female Adult Patients Receiving Glucocorticoid Therapy: A Pre-Post Controlled Study.

Authors:  Mei-Hua Chuang; Tzyy-Ling Chuang; Malcolm Koo; Yuh-Feng Wang
Journal:  Biomed Res Int       Date:  2017-01-03       Impact factor: 3.411

8.  The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence".

Authors:  Rosario Pivonello; Giorgio Arnaldi; Carla Scaroni; Carla Giordano; Salvo Cannavò; Davide Iacuaniello; Laura Trementino; Marialuisa Zilio; Valentina Guarnotta; Adriana Albani; Alessia Cozzolino; Grazia Michetti; Marco Boscaro; Annamaria Colao
Journal:  Endocrine       Date:  2019-04-09       Impact factor: 3.633

9.  Long-term outcome in patients after treatment for Cushing's disease in childhood.

Authors:  Katarzyna Pasternak-Pietrzak; Elżbieta Moszczyńska; Marcin Roszkowski; Karolina Kot; Elżbieta Marczak; Wiesława Grajkowska; Maciej Pronicki; Mieczysław Szalecki
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

10.  Cushing Syndrome Associated Myopathy: It Is Time for a Change.

Authors:  Martin Reincke
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.